![logo](/logos/ALDX.webp)
Aldeyra Therapeutics, Inc.
NASDAQ:ALDX
6.13 (USD) • At close September 6, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Aldeyra Therapeutics, Inc. |
Symbool | ALDX |
Munteenheid | USD |
Prijs | 6.13 |
Beurswaarde | 364,254,408 |
Dividendpercentage | 0% |
52-weken bereik | 1.42 - 7.42 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Todd C. Brady M.D., Ph.D. |
Website | https://www.aldeyra.com |
An error occurred while fetching data.
Over Aldeyra Therapeutics, Inc.
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-629, a
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)